Management and Board of Directors
Nathan Magarvey, PhD
Dr. Nathan Magarvey is the Founder and Chief Scientific Officer of Adapsyn Bioscience, and is responsible for all aspects of the company’s current collaboration with Pfizer. Additionally, he is an Associate Professor and Canada Research Chair in Natural Products and Chemical Biology in the Department of Biochemistry and Biomedical Sciences & Chemistry and Chemical Biology at McMaster University. He joined McMaster from Harvard Medical School and previously spent time in the pharmaceutical industry working for Wyeth Research, where he was directly involved in the discovery of new antibiotic and therapeutic microbial natural product small molecules. Dr. Magarvey’s research focuses on disrupting how the discovery of microbial metabolites is done- and in particular how to leverage the ability to connect Genomes to Natural Products, and his research has advanced the discovery of new microbial small molecules. His work leads to research intersecting the interfaces of medicine, biology, chemistry and computer science.
Andy Haigh, PhD MBA
Dr. Andrew (Andy) Haigh is Adapsyn’s Chief Operating Officer and has been working with the company since its inception. Prior to Adapsyn, Andy was the second employee at Formation Biologics, an antibody-drug conjugates that has raised over $20 million to date to fuel clinical development. Additionally, he spent five years at Lumira Capital, a leading Canadian venture capital firm, where he executed both equity and debt transactions and performed a variety of strategic, financial, operational, and business due diligence and analyses on numerous public and private companies. Prior to joining Lumira Capital, Andy worked for the MaRS and HTX – The Health Technology Exchange. Andy holds a PhD in Biology from Dalhousie University and an MBA from the Ivey Business School, which he attended on full scholarship from the Canadian Institutes of Health Research.
Iain Buchanan joins Adapsyn as Chairman of the Board and brings to the company over 40 years of management experience in the Pharmaceutical and Biotech industries. He currently also serves as a non-executive director of Allecra Therapeutics GmbH in Germany and of Synairgen plc based in Southampton, U.K. Most recently Mr. Buchanan held the position of Chief Executive Officer of NOXXON Pharma AG in Berlin from 2010 through 2015. Previously Mr. Buchanan was Chief Executive Officer of Novexel S.A. in Paris. He joined the Novexel upon its creation as the anti-infective spin out of Sanofi-Aventis in 2004 until its sale to AstraZeneca in 2010. Prior to joining Novexel, Mr. Buchanan held a variety of management positions of increasing responsibility across various companies. These include Vertex Pharmaceuticals, where he was responsible for building a presence in Europe from 1994 to 2004, Cilag A.G. (a division of Johnson and Johnson based in Zug, Switzerland), where he managed the international licensee business, and Biogen S.A. in Geneva, Switzerland, where he oversaw commercial activities in Europe. Mr Buchanan began his career in product management with Merck Sharp & Dohme (UK) Limited. He holds a Bachelor of Science in Physiology from the University of St. Andrews, Scotland.
Margi McLoughlin, PhD
Margi McLoughlin is an Executive Director in Worldwide Business Development (WWBD) at Pfizer based in South San Francisco, CA. Margi currently works with Pfizer’s Worldwide R&D (WRD) organization and Pfizer Venture Investments to manage Pfizer’s R&D Innovate (RDI) initiative to invest in companies working in areas aligned with the future directions of WRD. In RDI, she serves on the boards of 4D Molecular Therapeutics, Adapsyn, BioAtla and Cortexyme. Through these investments, she works with the companies and WRD leadership to help advance products and technologies of value to the pharmaceutical industry.
Margi held a position in Discovery Research at Mallinckrodt Medical, developing diagnostic pharmaceuticals for nuclear medicine, MR and X-ray imaging. After five years in the laboratory, Margi spent two years in Technology Planning at Mallinckrodt Medical, where she supported internal R&D through outside alliances. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Pfizer in 2001, she has had roles of increasing responsibility in WWBD and has had a significant role in defining Pfizer’s Centers for Therapeutic Innovation and led transactions with multiple biotech companies, including Ablexis, Gliknik, Excaliard, and others.
Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 30 investments. He currently serves on the Board of Directors of Functional Neuromodulation Ltd. and Adapsyn Bioscience Inc. From 2012-2015, he was a board observer with Invitae (NYSE: NVTA), and from 2001 to 2013, he served on the board of Epocal (acquired by Alere, NYSE: ALR). Mr. Holman also sits on the Board of Directors of the Ontario Biotechnology Innovation Organization (OBIO). Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer’s disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s.